GALNT2 can modify IGF-1R O-glycosylation and interfere with IGF-1-triggered dimerization and activity of IGF-1R, thereby regulating downstream signaling events related to malignant properties of NB cells in vitro and tumor growth in vivo. This evidence concerns the gene IGF1R and neoplasm.